As reported in Biospectrum Asia, Australia’s University of Wollongong (UOW) will continue to collaborate with pharmaceutical firm Phebra. UOW researchers Dr. Carolyn Dillon and Ms. Judith Carrall have recognized the well-established efficacy of arsenic in the treatment of acute promyelocytic Leukemia (APL). UOW has since developed a new concept that promises to allow the dose of cytotoxoc arsenic to be reduced by up to forty-fold. Moreover, it has been designed to specifically target cancers that are sensitive to treatment by this drug. Phebra will license the intellectual property from UOW.
Phebra Chief Executive, Dr Mal Eutick, said that the researchers had already seen positive indications in the in vitro trials to date, with the new arsenic compound successfully targeting a number of cancers including APL, Acute Myeloid Leukemia (AML) and potentially pancreatic cancer.
The terms of the arrangement were not published. If TrialSite News readers request more information, our staff can research deal terms.
Dr. Carolyn Dillon, University of Wollongong
Judith Carrall, University of Wollongong